23G pars plana vitrectomy for vitreal floaters: prospective assessment of subjective self-reported visual impairment and surgery-related risks during the course of treatment

  • Ursula Hahn
  • Frank Krummenauer
  • Klaus Ludwig
Retinal Disorders



Quantifying the subjective impairment due to floaters based on an indication-specific questionnaire and setting its change between prior to and 3/12 months after elective vitrectomy in relation to surgical risks.


Single-arm longitudinal observational multicenter study. Sixty-four floater patients underwent 23G pars plana vitrectomy; simultaneous phacoemulsification was excluded. An overall self-rated impairment index (SRI) and sub-indices SRI were calculated on the basis of a modified Visual Quality of Life questionnaire (VQoL), which addresses general vision, glare, near-sight problems and mobility of floaters. SRI ranged from 0 to 100% (maximum impairment). Secondary endpoints included corrected visual acuity and complications.


Data were collected prior to and 3 (n = 64) and 12 (n = 62) months after surgery. The median overall SRI improved (44, 12, 11%) with a statistically significant median reduction of 69% (95% confidence interval 50–89%) 3 months postop. The median sub-SRIs improved for glare (50, 17, 17%), near sight problems (50, 17, 8%), and mobility of floaters (43, 5, 0%). Sixteen eyes needed cataract surgery during follow-up (10 showed cataract already prior to vitrectomy). Eight complications were reported (6 intra-operative retinal holes, 2 post-operative retinal detachments).


For the majority of floater patients, subjective impairment was profoundly reduced by vitrectomy. Benefits of surgery prevailed despite complications.


Floaters Mouches volantes Pars Plana vitrectomy Prospective multicenter study Quality of life Subjective impairment 



The authors thank Dr. NA Frost for the permission to use the Visual Quality of Life questionnaire for developing the Floaters questionnaire. Furthermore, the authors are grateful to Mrs. Nicole Waack for study coordination, to Mrs. Levka Dahmen for assistance in data management, and to Mrs. Tara Rödter and to Mrs. Chui Lai Choo-Ludwig for revising the paper focusing on syntax as well as comprehensibility.

The OcuNet Trial Group thank Alcon Pharma GmbH, Freiburg, for supporting the study financially.

Participating study physicians

Dr. H. Kaymak, Gerl-Gruppe, Augenklinik Ahaus, Ahaus

Prof. K. Ludwig, Ober Scharrer Gruppe, ARIS MVZ Nuremberg, Nuremberg

Dr. O. Cartsburg, Augen-Zentrum-Nordwest, Augenpraxis Ahaus, Ahaus

Dr. A. Lommatzsch, Augenärzte am St. Franziskus Hospital, Muenster

Dr. T. Littan, Augenpraxisklinik Lohr, Lohr

Dr. U. Weigmann, Augenklinik Dr. Hoffmann, Braunschweig

Dr. P. Requat, Augenklinik Dr. Hoffmann, Braunschweig

Dr. A. Bunse, Augenärzte Hamburg-Bergedorf, Dr. Bunse Dr. Elsner Dr. Pörksen, Hamburg

Dr. S. Spang, Augen-Partner-Gruppe, Augenzentrum Tuttlingen, Tuttlingen


This study was funded by Alcon Pharma GmbH, Freiburg: funding was used for clinical project management resources and administrated by U Hahn (OcuNet).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The coordinating Independent Ethics Committee (Bavaria) gave unrestricted consent to the investigation design at hand by its vote in 08 / 2011; so did all local Committees subsequently in accordance with this vote.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Milston R, Madigan MC, Sebag J (2016) Vitreous floaters: etiology, diagnostics, and management. Surv Ophthalmol 61(2):211–227. CrossRefPubMedGoogle Scholar
  2. 2.
    Sebag J (1989) The vitreous—structure, function an pathobiology. Springer-Verlag, New YorGoogle Scholar
  3. 3.
    Serpetopoulos CN, Korakitis RA (1998) An optical explanation of the entoptic phenomenon of ‘clouds’ in posterior vitreous detachment. Ophthalmic Physiol Opt 18(5):446–451CrossRefPubMedGoogle Scholar
  4. 4.
    Sebag J, Yee KM, Wa CA, Huang LC, Sadun AA (2014) Vitrectomy for floaters: prospective efficacy analyses and retrospective safety profile. Retina 34(6):1062–1068. CrossRefPubMedGoogle Scholar
  5. 5.
    Wagle AM, Lim WY, Yap TP, Neelam K, Au Eong KG (2011) Utility values associated with vitreous floaters. Am J Ophthalmol 152(1):60–65 e61. CrossRefPubMedGoogle Scholar
  6. 6.
    Koo EH, Haddock LJ, Bhardwaj N, Fortun JA (2016) Cataracts induced by neodymium-yttrium-aluminium-garnet laser lysis of vitreous floaters. Br J Ophthalmol
  7. 7.
    Cowan LA, Khine KT, Chopra V, Fazio DT, Francis BA (2015) Refractory open-angle glaucoma after neodymium-yttrium-aluminum-garnet laser lysis of vitreous floaters. Am J Ophthalmol 159(1):138–143. CrossRefPubMedGoogle Scholar
  8. 8.
    Mason JO 3rd, Neimkin MG, JOt M, Friedman DA, Feist RM, Thomley ML, Albert MA (2014) Safety, efficacy, and quality of life following sutureless vitrectomy for symptomatic vitreous floaters. Retina 34(6):1055–1061. CrossRefPubMedGoogle Scholar
  9. 9.
    de Nie KF, Crama N, Tilanus MA, Klevering BJ, Boon CJ (2013) Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction. Graefes Arch Clin Exp Ophthalmol 251(5):1373–1382. CrossRefPubMedGoogle Scholar
  10. 10.
    Schulz-Key S, Carlsson JO, Crafoord S (2011) Longterm follow-up of pars plana vitrectomy for vitreous floaters: complications, outcomes and patient satisfaction. Acta Ophthalmol
  11. 11.
    Tan HS, Mura M, Lesnik Oberstein SY, Bijl HM (2011) Safety of vitrectomy for floaters. Am J Ophthalmol 151(6):995–998. CrossRefPubMedGoogle Scholar
  12. 12.
    Hoerauf H, Muller M, Laqua H (2003) Vitreous body floaters and vitrectomy with full visual acuity. Ophthalmologe 100(8):639–643. CrossRefPubMedGoogle Scholar
  13. 13.
    Schiff WM, Chang S, Mandava N, Barile GR (2000) Pars plana vitrectomy for persistent, visually significant vitreous opacities. Retina 20(6):591–596CrossRefPubMedGoogle Scholar
  14. 14.
    Frost NA, Sparrow JM, Durant JS, Donovan JL, Peters TJ, Brookes ST (1998) Development of a questionnaire for measurement of vision-related quality of life. Ophthalmic Epidemiol 5(4):185–210CrossRefPubMedGoogle Scholar
  15. 15.
    Cohen MN, Rahimy E, Ho AC, Garg SJ (2015) Management of symptomatic floaters: current attitudes, beliefs, and practices among vitreoretinal surgeons. Ophthalmic Surg Lasers Imaging Retina 46(8):859–865. CrossRefPubMedGoogle Scholar
  16. 16.
    Castilla-Marti M, van den Berg TJ, de Smet MD (2015) Effect of vitreous opacities on straylight measurements. Retina 35(6):1240–1246. CrossRefPubMedGoogle Scholar
  17. 17.
    Qiao L, Wan X, Cai X, Vasudevan B, Xiong Y, Tan J, Guan Z, Atchison DA, Wang N (2014) Comparison of ocular modulation transfer function determined by a ray-tracing aberrometer and a double-pass system in early cataract patients. Chin Med J 127(19):3454–3458PubMedGoogle Scholar
  18. 18.
    Garcia GA, Khoshnevis M, Yee KM, Nguyen-Cuu J, Nguyen JH, Sebag J (2016) Degradation of contrast sensitivity function following posterior vitreous detachment. Am J Ophthalmol
  19. 19.
    Feng H, Adelman RA (2014) Cataract formation following vitreoretinal procedures. Clin Ophthalmol 8:1957–1965. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute for Medical Biometry and Epidemiology, Faculty of HealthWitten/Herdecke UniversityWittenGermany
  2. 2.OcuNet Trial GroupDuesseldorfGermany
  3. 3.ARIS AugenklinikNurembergGermany

Personalised recommendations